Research programme: antibody-drug conjugates - Bayer HealthCare

Drug Profile

Research programme: antibody-drug conjugates - Bayer HealthCare

Alternative Names: Anti-C4.4a antibody-drug conjugates; Anti-C4.4a-ADC; Anti-LY6-PLAUR domain containing 3 antibody-drug conjugates; Antibody-Eg5 inhibitor conjugates; Antibody-KIF11 inhibitor conjugates; Antibody-kinesin spindle protein inhibitor conjugates; Antibody-KSP inhibitor conjugates; FGFR2-ADC

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Seattle Genetics
  • Class Antibodies; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action Apoptosis stimulants; KIF11 protein inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Sep 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 01 Apr 2017 Pharmacodynamics data from preclinical trials in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 02 Sep 2016 The programme is still under preclinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top